$2.340
-0.010 (-0.43%)At close
ZJYL News
ZJYL Events
Jin Medical International Ltd Trading Halted, News Pending
Jin Medical International Ltd trading halted, news pending
Jin Medical launches production at Plant No. 3
Jin Medical announced that its wholly owned subsidiary, ZhongJin Medical Equipment, has officially launched production at Plant No. 3 of Zhongjin Anhui's manufacturing facility in Chuzhou, Anhui, China. The company's products span across the 5.5 kg ultra-light wheelchair, competition-grade equipment certified by the International Paralympic Committee, micro hyperbaric oxygen chambers dedicated to health and wellness and beauty devices that extend into lifestyle aesthetics. As of the date hereof, the latest batch of electric wheelchairs is undergoing rigorous vibration testing. The company plans to supply these units to senior care communities in Istanbul, rehabilitation centers in Jerusalem, and home clinics in Tokyo. With these products, Jin Medical is committed to using technology to overcome geography and access barriers.
Jin Medical receives noncompliance notification from Nasdaq
Jin Medical announced that it received a deficiency letter from the Nasdaq. The notice informed the company that, based upon the closing bid price of the company's ordinary shares over the 30 consecutive business day period between March 20 and May 1 the company is not in compliance with the requirement to maintain a minimum bid price of $1.00 per share of its ordinary shares for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550.
Jin Medical announces initiation of construction of new manufacturing facility
Jin Medical announced the initiation of construction of JinMed's new manufacturing facility at Chuzhou City, Anhui Province, China. JinMed, a newly established subsidiary of JinMed, will be designated to operate the Chuzhou JinMed plant which is established as an internationally standardized, innovative, and high-end wheelchair and electric wheelchair manufacturing factory. With higher-level production lines in place, more innovative high-quality products are expected to strengthen JinMed's leadership in the AT industry.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.